Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro
Journal of Antimicrobial Chemotherapy · 04.03.2026 · 81 (4)
DOI: 10.1093/jac/dkag058 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.03.2026. Verfasst von Hafsa Abduljalil und 6 weiteren Autor:innen. Beteiligte Einrichtung: Safeguarding Health Through Infection Prevention (SHIP) Research Group, Research Centre for Health, School of Health and Life Sciences, Glasgow Caled…. Hauptthemen laut MEDLINE: Biofilms, Antifungal Agents, Echinocandins, Candida. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MundiPharma.
Abstract (Originalsprache)
Objectives
We sought to evaluate the comparative activity of rezafungin compared with caspofungin and other antifungal classes against biofilms from a large clinical panel of Candida strains (n = 167).
Methods
Biofilm killing and inhibition were assessed using standard XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt] metabolic assessment. Biofilm time–kill kinetics were also evaluated using metabolic and viable cell counts. Microscopy was performed to visually assess biofilm inhibition.
Results
Rezafungin was shown to outperform caspofungin and other antifungals against C. albicans, C. parapsilosis, C. tropicalis and Nakaseomyces glabratus (previously called C. glabrata) strains with a heterogeneous biofilm phenotype. Assessment of high biofilm-forming strains at 0.03 mg/L concentrations showed that rezafungin killed biofilms to an equal or greater extent than caspofungin. Time–kill studies showed a rapid reduction in metabolism and viable cfus by both rezafungin and caspofungin, but with little difference between both compounds. Evaluation of biofilm inhibition characteristics of both compounds showed that rezafungin was marginally more effective than caspofungin, which was corroborated by microscopical analyses.
Conclusions
Together, these data show that rezafungin is non-inferior to caspofungin in terms of anti-biofilm activity and displays characteristics that suggest it can control biofilms more effectively than caspofungin. Further evaluation is required to establish whether these in vitro effects translate clinically, but the data indicate an opportunity for rezafungin to be used for the clinical management of biofilm-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Safeguarding Health Through Infection Prevention (SHIP) Research Group, Research Centre for Health, School of Health and Life Sciences, Glasgow Caledonian University, 70 Cowcaddens Road, Glasgow G4 0BA, UK.
- Microbiology Department, Glasgow Royal Infirmary, Glasgow G4 0SF, UK.
- Mycology Reference Centre Manchester, ECMM Centre of Excellence, and Department of Infectious Diseases, Wythenshawe Hospital, Manchester University NHS Foundation Trust, UK; and Manchester Biomedical Research Centre, Di…
- Microbiology Department, Lancaster Royal Infirmary, Lancaster, UK.
ORCID-Profile: Kerry Bartie, Abhijit M Bal, Riina Rautemaa-Richardson, Craig Williams, Ryan Kean, Gordon Ramage
Förderung
- MundiPharma
Zitieren
APA
Abduljalil, H., Bartie, K., Bal, A. M., Rautemaa-Richardson, R., Williams, C., Kean, R., & Ramage, G. (2026). Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro. Journal of Antimicrobial Chemotherapy, 81(4). https://doi.org/10.1093/jac/dkag058
Vancouver
Abduljalil H, Bartie K, Bal AM, Rautemaa-Richardson R, Williams C, Kean R, et al. Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro. Journal of Antimicrobial Chemotherapy. 2026;81(4). doi:10.1093/jac/dkag058
BibTeX
@article{Abduljalil2026,
author = {Abduljalil, Hafsa and Bartie, Kerry and Bal, Abhijit M and Rautemaa-Richardson, Riina and Williams, Craig and Kean, Ryan and Ramage, Gordon},
title = {Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {4},
doi = {10.1093/jac/dkag058}
}
EUVIMED